CNS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.23 USD | -7.85% |
|
-38.12% | -96.47% |
| 14/06 | CNS Pharmaceuticals, Inc. announced that it expects to receive $1.3725 million in funding | CI |
| 10/06 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 64.97 | 41.13 | 19.61 | 3.203 | 6.666 |
| Enterprise Value (EV) 1 | 57.73 | 27.53 | 14.99 | -6.443 | 6.418 |
| P/E ratio | - | -3.13 x | -1.32 x | -0.21 x | -0.25 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -1,50,69,693 x | -29,15,073 x | -10,69,910 x | 4,22,336 x | -3,40,266 x |
| EV / FCF | -21.8 x | -6.44 x | -1.93 x | 1.12 x | -0.8 x |
| FCF Yield | -4.58% | -15.5% | -51.9% | 89% | -125% |
| Price to Book | 8.55 x | 3.04 x | 2.96 x | 0.48 x | -1.78 x |
| Nbr of stocks (in thousands) | 11 | 15.4 | 18.6 | 26.7 | 105 |
| Reference price 2 | 5,925 | 2,670 | 1,054 | 120.0 | 63.50 |
| Announcement Date | 12/03/20 | 12/02/21 | 03/03/22 | 31/03/23 | 01/04/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | -3.831 | -9.444 | -14.01 | -15.26 | -18.86 |
| EBIT 1 | -0.8818 | -3.833 | -9.455 | -14.03 | -15.27 | -18.87 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.392 | -3.877 | -9.458 | -14.04 | -15.27 | -18.85 |
| Net income 1 | -7.392 | -3.877 | -9.458 | -14.04 | -15.27 | -18.85 |
| Net margin | - | - | - | - | - | - |
| EPS | - | - | -853.7 | -798.9 | -561.0 | -250.2 |
| Free Cash Flow 1 | 0.1111 | -2.646 | -4.273 | -7.777 | -5.734 | -8.003 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/03/19 | 12/03/20 | 12/02/21 | 03/03/22 | 31/03/23 | 01/04/24 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -2.793 | -2.782 | -3.564 | -3.419 | -4.025 | -4.534 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.795 | -2.784 | -3.566 | -3.42 | -4.021 | -4.523 |
| Net income 1 | -2.795 | -2.784 | -3.566 | -3.42 | -4.021 | -4.523 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -150.0 | -105.0 | -135.0 | -135.0 | -52.00 | -54.00 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 03/03/22 | 13/05/22 | 12/08/22 | 10/11/22 | 14/08/23 | 14/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.03 | - | - | - | - | - |
| Net Cash position 1 | - | 7.24 | 13.6 | 4.62 | 9.65 | 0.25 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 0.11 | -2.65 | -4.27 | -7.78 | -5.73 | -8 |
| ROE (net income / shareholders' equity) | 2,432% | -110% | -87.8% | -136% | -214% | -1,019% |
| ROA (Net income/ Total Assets) | -130% | -55.7% | -49.7% | -71.2% | -87.5% | -160% |
| Assets 1 | 5.67 | 6.956 | 19.02 | 19.7 | 17.46 | 11.79 |
| Book Value Per Share | - | 693.0 | 877.0 | 356.0 | 251.0 | -35.70 |
| Cash Flow per Share | - | 660.0 | 883.0 | 269.0 | 311.0 | 4.410 |
| Capex | - | 0.02 | 0.02 | 0.01 | 0 | 0 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 28/03/19 | 12/03/20 | 12/02/21 | 03/03/22 | 31/03/23 | 01/04/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -96.47% | 574K | |
| +35.25% | 51.07B | |
| -8.18% | 38.78B | |
| +35.11% | 38.61B | |
| -8.98% | 27.32B | |
| +11.54% | 26.35B | |
| -19.18% | 19.46B | |
| +40.70% | 13.58B | |
| +30.46% | 12.46B | |
| -4.13% | 11.75B |
- Stock Market
- Equities
- CNSP Stock
- Financials CNS Pharmaceuticals, Inc.
